Candidiasis - Pipeline Review, H1 2018

  • ID: 4464902
  • Drug Pipelines
  • 172 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bakker Medical Srl
  • Beta Pharma Inc
  • Biosergen AS
  • Cidara Therapeutics Inc
  • Dermala Inc
  • Gedea Biotech AB
  • MORE
Candidiasis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H1 2018, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 8, 2, 1, 23, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 14 and 7 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bakker Medical Srl
  • Beta Pharma Inc
  • Biosergen AS
  • Cidara Therapeutics Inc
  • Dermala Inc
  • Gedea Biotech AB
  • MORE
Introduction

Candidiasis - Overview

Candidiasis - Therapeutics Development

Candidiasis - Therapeutics Assessment

Candidiasis - Companies Involved in Therapeutics Development

Candidiasis - Drug Profiles

Candidiasis - Dormant Projects

Candidiasis - Discontinued Products

Candidiasis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Candidiasis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2018

Candidiasis - Pipeline by Bakker Medical Srl, H1 2018

Candidiasis - Pipeline by Beta Pharma Inc, H1 2018

Candidiasis - Pipeline by Bionex Pharmaceuticals LLC, H1 2018

Candidiasis - Pipeline by Biosergen AS, H1 2018

Candidiasis - Pipeline by Cidara Therapeutics Inc, H1 2018

Candidiasis - Pipeline by Dermala Inc, H1 2018

Candidiasis - Pipeline by Gedea Biotech AB, H1 2018

Candidiasis - Pipeline by General Biologicals Corp, H1 2018

Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H1 2018

Candidiasis - Pipeline by iCo Therapeutics Inc., H1 2018

Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H1 2018

Candidiasis - Pipeline by Nanomerics Ltd, H1 2018

Candidiasis - Pipeline by Nosopharm SAS, H1 2018

Candidiasis - Pipeline by Novabiotics Ltd, H1 2018

Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H1 2018

Candidiasis - Pipeline by Novartis AG, H1 2018

Candidiasis - Pipeline by Onxeo SA, H1 2018

Candidiasis - Pipeline by Scynexis Inc, H1 2018

Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2018

Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H1 2018

Candidiasis - Pipeline by Visterra Inc, H1 2018

Candidiasis - Pipeline by Wellstat Vaccines LLC, H1 2018

Candidiasis - Dormant Projects, H1 2018

Candidiasis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Candidiasis - Dormant Projects, H1 2018 (Contd..2), H1 2018

Candidiasis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Candidiasis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amplyx Pharmaceuticals Inc
  • Bakker Medical Srl
  • Beta Pharma Inc
  • Bionex Pharmaceuticals LLC
  • Biosergen AS
  • Cidara Therapeutics Inc
  • Dermala Inc
  • Gedea Biotech AB
  • General Biologicals Corp
  • Grupo Ferrer Internacional SA
  • iCo Therapeut
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll